Antibodies have proven hugely successful in treatment of human disease, Many factors have been identified to influence the efficacy and safety for current therapies.
Discrimination between membrane bound or shed antigens could resolve some of the major hurdles encountered with current therapies and targets to expand indications.
Learn more
Our most promising antibody is a humanised IgG1 antibody that blocks IL-6 trans signalling without affecting IL-6 classical signalling.
All IL-6 antibodies in the clinic block both pathways, limiting use to a few disease areas.
Learn more
Mab Designs Ltd was founded in 2009 to develop antibodies which exploit the selectivity of an antibody or fab structure for the conformation of its target antigen and thereby enhance the delivery and efficacy of therapeutic agents and diagnostics. IP optionality is not limited to the discriminating antibody technology and can be expanded by molecular enhancements or a separate formulation to optimise for the indication targeted.
Our goal is to work alongside partners to improve the selectivity and focus efficacy for selected target antigens and enhance the potential of those under development.
More
Call today on +44 7771 641570 or email andy@mabdesigns.co.uk
Scan this code with an authenticator app, such as Authy or Google Authenticator, preferably on a different device, then type in the access code it shows below and click OK to check it has been set up correctly. Then save your profile and then when you sign in you will be prompted for an access code, open your authenticator to get the current value and type it in.
Page: index